Market Closed -
Japan Exchange
11:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
739
JPY
|
-1.34%
|
|
+3.36%
|
-3.02%
|
Fiscal Period: December |
2022
|
2023
|
---|
Capitalization
1 |
9,559
|
5,957
|
Enterprise Value (EV)
1 |
6,029
|
2,997
|
P/E ratio
|
-7.34
x
|
-10.1
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
25.6
x
|
97.7
x
|
EV / Revenue
|
16.1
x
|
49.1
x
|
EV / EBITDA
|
-1,66,54,247
x
|
-45,61,313
x
|
EV / FCF
|
-1,31,63,400
x
|
-67,06,087
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
2.22
x
|
1.86
x
|
Nbr of stocks (in thousands)
|
7,347
|
7,817
|
Reference price
2 |
1,301
|
762.0
|
Announcement Date
|
28/03/23
|
27/03/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
137
|
708
|
374
|
61
|
EBITDA
|
-
|
-
|
-362
|
-657
|
EBIT
1 |
-372
|
71
|
-425
|
-697
|
Operating Margin
|
-271.53%
|
10.03%
|
-113.64%
|
-1,142.62%
|
Earnings before Tax (EBT)
1 |
-327
|
144
|
-471
|
-586
|
Net income
1 |
-329
|
142
|
-473
|
-589
|
Net margin
|
-240.15%
|
20.06%
|
-126.47%
|
-965.57%
|
EPS
2 |
-657.3
|
283.7
|
-177.3
|
-75.39
|
Free Cash Flow
|
-
|
-
|
-458
|
-446.9
|
FCF margin
|
-
|
-
|
-122.46%
|
-732.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/10/22
|
27/10/22
|
28/03/23
|
27/03/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,545
|
1,846
|
3,530
|
2,960
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-458
|
-447
|
ROE (net income / shareholders' equity)
|
-
|
8.23%
|
-16.7%
|
-16.9%
|
ROA (Net income/ Total Assets)
|
-
|
1.83%
|
-7.12%
|
-9.65%
|
Assets
1 |
-
|
7,747
|
6,643
|
6,104
|
Book Value Per Share
2 |
3,095
|
3,796
|
585.0
|
409.0
|
Cash Flow per Share
2 |
4,140
|
4,821
|
689.0
|
495.0
|
Capex
|
-
|
-
|
228
|
19
|
Capex / Sales
|
-
|
-
|
60.96%
|
31.15%
|
Announcement Date
|
27/10/22
|
27/10/22
|
28/03/23
|
27/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.02% | 36.8M | | +38.65% | 39.1B | | -7.53% | 38.76B | | +27.49% | 31.24B | | +13.26% | 25.9B | | -13.50% | 25.8B | | +45.70% | 14.06B | | +40.24% | 13.12B | | -6.74% | 11.32B | | -11.92% | 10.68B |
Other Biotechnology & Medical Research
|